The outcome of hepatitis B virus (HBV) infection is determined by the complex interaction between the host's immune system and the virus and the proteins it produces, leading to the occurrence of acute and chronic liver diseases. In acute hepatitis B (AHB), the virus is cleared by the host through innate immunity and strong adaptive immunity. In chronic hepatitis B (CHB), both the innate and adaptive immunity of the host are continuously inhibited by HBV and the proteins it produces, which are not conducive to virus clearance. This article reviews the recent studies on innate immunity and adaptive immunity of acute and chronic viral hepatitis B, in order to provide ideas for further research and provide evidence for new clinical treatment method.